Replies

FTA ....

...Nattokinase is dosed in fibrinolytic units (FU) per gram and can vary according to purity. Kurosawa and colleagues have shown in humans that after a single oral dose of 2000 FU D-dimer concentrations at 6, and 8 hours, and blood fibrin/fibrinogen degradation products at 4 hours after administration elevated significantly (p < 0.05, respectively). Thus an empiric starting dose could be 2000 FU twice a day. Full pharmacokinetic and pharmacodynamic studies have not been completed, but several years of market use as an over-the-counter supplement suggests nattokinase is safe with the main caveat being excessive bleeding and cautions with concurrent antiplatelet and anticoagulant drugs.

Based on these findings, nattokinase and similar products such as serrapeptase should undergo well-funded, accelerated preclinical and clinical development programs. The issue at hand is the urgency of time, similar to that with SARS-CoV-2 infection and empiric early therapy. It will take up to 20 years to have a fully developed pharmaceutical profile to characterize the safety and efficacy of nattokinase in the treatment of vaccine injury and post-COVID syndromes. Large number of people are sick now and many believe empiric treatment is justified given sufficiently low risk of side effects and potentially high reward. My recommendation is to discuss this with your doctor or seek a specialist in holistic or naturopathic medicine who is experienced with the safety profile of nattokinase in a range of applications....